Illustrative estimate only - not verified by this sponsor. Contact the study team for actual compensation.
The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.
What happens when you apply
Reach out via phone or email to express interest
Brief call to discuss your health history
Medical screening at the research site
Begin your journey in the study
Inclusion Criteria: * Adults aged 50 to 80 years * General good health * Willing to comply with all study-related procedures and visits * Participant is open to morphological change * If female, participant agrees to maintain contraception * If female, participant agrees to take a pregnancy test * If female, participant agrees to a pregnancy waiver Exclusion Criteria: * Currently enrolled in another clinical trial * History of cancer, autoimmune disease, or chronic kidney/liver disease * Use of immunosuppressive therapy * Pregnant or breastfeeding * Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study. * Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine, etc.) * Regular use of antiplatelet medications (i.e., aspirin) * Any medical or psychiatric condition that could interfere with participation or pose safety concerns * Unwilling or unable to provide informed consent
imaguineapig pulls live data from ClinicalTrials.gov (NIH/NLM).Illustrative estimate only - not verifiedPay estimates are approximate ranges based on study type and are not confirmed by sponsors — actual compensation may differ. Eligibility indicators use limited criteria (age, sex) only. We do not provide medical advice. Always contact the study team directly to confirm compensation, full eligibility, and risks before enrolling.